Is fractionated stereotactic radiotherapy effective in pituitary adenomas?

Nature Clinical Practice Oncology

Volumn 2, Issue 11, 2005, Pages 548-549

  Loeffler, Jay S ^a   Nachtigall, Lisa B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adenoma; Fractionated; Pituitary; Stereotactic; Toxicity

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; KETOCONAZOLE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; BLOOD VESSEL INJURY; BRAIN NECROSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; CUSHING DISEASE; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; PROLACTINOMA; RADIATION DOSE; RADIATION SICKNESS; SHORT SURVEY; STATISTICAL ANALYSIS; STEREOTAXIC SURGERY; TUMOR; TUMOR GROWTH; VISUAL IMPAIRMENT;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DOSE FRACTIONATION; HUMANS; MIDDLE AGED; PITUITARY IRRADIATION; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; STEREOTAXIC TECHNIQUES; TREATMENT OUTCOME;

EID: 28444433436     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0327     Document Type: Short Survey

References (2)

1. Shrieve DC et al. (1997) Fractionated (relocatable) stereotactic radiotherapy. In Cancer: Principles and Practice of Oncology, 3107-3114 (Eds DeVita VT et al.) Philadelphia: Lippincott-Raven
2. Sheehan JP et al. (2005) Stereotactic radiosurgery for pituitary adenomas: An intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102: 678-691